Ublituximab- TG Therapeutics

Drug Profile

Ublituximab- TG Therapeutics

Alternative Names: EMAB-6; LFB-R603; R603; TG-1101; TGTX-1101; Utuxin

Latest Information Update: 02 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator LFB Biotechnologies; rEVO Biologics
  • Developer Johns Hopkins University; LFB Biotechnologies; TG Therapeutics Inc
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action CD antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuromyelitis optica; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; Diffuse large B cell lymphoma; Marginal-zone-B-cell-lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic lymphocytic leukaemia; Multiple sclerosis
  • Phase II Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma
  • Phase I/II Non-Hodgkin's lymphoma
  • Phase I Neuromyelitis optica

Most Recent Events

  • 20 Dec 2017 TG Therapeutics and Wilmot Cancer Institute - University of Rochester plan a phase I/II trial for Chronic lymphocytic leukaemia (Combination therapy, Second-line therapy or greater) in USA (NCT03379051)
  • 11 Dec 2017 Efficacy and adverse events data from a phase I/II trial in Chronic lymphocytic leukaemia (Combination therapy, Second-line therapy or greater) presented at the 59th American Society of Haematology (ASH-2017)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in Chronic-lymphocytic-leukaemia(Monotherapy, Second-line therapy or greater) in France (IV, Infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top